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Abstract
Fucoxanthin is a carotenoid sourced and extracted mainly from dark orange and
brown seaweeds found in the pacific ocean, such as the wakame algae. The allenic bonds
and unique oxygen groups give fucoxanthin its unique structure and are thought to be part
of the reason fucoxanthin has unique physiological functions. Fucoxanthin has potentially
numerous effects on the physiology of human health, ranging from skin health to
metabolic health, which have been demonstrated in animal model research. The goal of
this review is to examine current literature to discuss fucoxanthin’s potential application
as a nutraceutical, treatment for obesity, type 2 diabetes, chronic inflammation, and
dyslipidemia to provide an alternative, or additive treatment to pharmacoligcal
interventions.

v
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Chapter 1: Introduction
Fucoxanthin, a brown seaweed carotenoid, has the potential to be used to
ameliorate a host of health issues, ranging from dermatitis1 and skin wrinkling 2 to
prevention and treatment of several types of cancer in mouse models3–7. Fucoxanthin
further provides benefits through unique mechanisms of action with regards to some of
the world's most far-reaching diseases, such as obesity, diabetes, and other inflammatory
diseases as shown in several murine model projects8–11. The unique actions of
fucoxanthin may prove to be a beneficial additive treatment, or even as a stand-alone
treatment option for those who prefer a holistic approach to health.
Fucoxanthin’s health benefits were first discussed in the late 1920s, as it was
noted to be in high quantities in cod liver oil, a successful treatment for rickets12. In
murine model research, the current literature now reveals fucoxanthin having benefits to
health beyond treating rickets and directly benefitting diseases such as diabetes, heart
disease, and obesity8–11. A small quantity of murine research emerged in the 2000s about
fucoxanthin’s health benefits, however, most of the research on fucoxanthin is related to
plant biology and physiology, leaving much to be explored in the field of human health
and physiology. Many of the research projects examining the health benefits of
fucoxanthin have been conducted in murine models, leaving a large gap in the literature
on the potential benefits to humans.
The objective of this paper is to review the current body of literature relative to
fucoxanthin’s potential benefits to human health and chronic disease management with
specific regards to adiposity, blood glucose, inflammation, and blood lipids.
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Chapter 2: Methods
Three online databases (PubMed, Scopus, and Alt HealthWatch) were reviewed
using the following search terms: “fucoxanthin” combined with “diabetes”, “UCP1”,
“Obesity”, “lipids”, and “inflammation”. Both animal and human research were included,
as human experimental data on fucoxanthin is currently limited. Peer-reviewed articles
reported in English from January 2000- March 2021 were included in the search review.
All research included were full-text articles available through the James Madison
University library databases at the time of authorship. (Figure 1)
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Chapter 3: Manuscript
History
The earliest mention of fucoxanthin’s potential health benefits was in 1928 from
Knut Wejdling, a Swedish researcher from Stockholm University. Wejdling was
investigating the antirachitic nature of cod liver oil and found that fucoxanthin may act as
a link for unsaturated carbon linkages found within cod liver. Wejdling hypothesized that
during the depigmentation of fucoxanthin within the livers of deep water cod, lipids were
released, yielding cod liver to become antiarachtic12.
The first true experimental trial showing fucoxanthin’s promising benefit to
human health was published in 1990 from Jyunichi Okuzumi’s research group from the
Kyoto Prefectural University of Medicine. Okuzumi’s group found that treating in-vitro
human malignant tumor cells with a 10 μg/ml fucoxanthin serum for three days reduced
the rate of growth of neuroblastoma cells to 38% of their original growth rates13. It was
revealed that fucoxanthin inhibited the G0-G1 phases of the cell cycle, being the initial
replicative steps of cell growth13. The same fucoxanthin serum reduced the expression of
N-myc proto-oncogene protein, a gene that is responsible for cell proliferation in cancer
cells13. Fucoxanthin was largely left unstudied in human trials following Okuzumi’s
findings until the early 2000’s when research groups found anti-cancer effects in human
prostate cells14,15, and inhibition of replicative DNA polymerase activity, lending
fucoxanthin to being coined as an anti-neoplastic compound16.
Between these first mentionings of fucoxanthin in cod liver oil and its later
application in its anti-cancer potential, most research about fucoxanthin was describing
its general contribution to plant biology. James Mann and Jack Myers from The
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University of Texas, Austin, discussed the fact that fucoxanthin was much more efficient
at energy transfer to chlorophyll during photosynthesis than other carotenoids17.
Fucoxanthin was also found to have significantly higher absorption rates of light across
various spectrums (450-700nm) compared to other carotenoids commonly found in algae
and referred to as Mann and Myers to be one of the most important
light-absorbing pigments for the photosynthetic process17.
Biological Properties
Contrasting with the majority of other carotenoids, fucoxanthin contains an
allenic bond as well as the oxygen functional groups: beta-gamma-epoxy ketone,
hydroxyl, carbonyl, and carboxyl groups18. Using ozonolysis to chemically degrade
fucoxanthin, two synthetic fucoxanthin metabolites, apo-9’-fucoxanthinone, and apo-13fucoxanthinone can be created19–21. Ozonolysis will chemically split the fucoxanthins
polyene chain into two groups, one being a group with an allenic bond, and the other
being a beta-gamma-epoxy ketone group21. Current literature would indicate that the two
synthetic metabolites seemingly function the same as their organic counterparts22.
In nature, carotenoids are absorbed by the Caco-2 cells in the intestinal lining, the
same pathway as dietary fat due to the fact that all carotenoids are hydrophobic similar to
lipids23. Fucoxanthin is metabolized into two different bioactive compounds,
fucoxanthinol and amarouciaxanthin, with fucoxanthin primarily metabolizing into
fucoxanthinol in the human gastrointestinal tract24. It has been suggested that lipase and
carboxylesterase are released for the enzymatic breakdown of fucoxanthin in the
gastrointestinal tract, and the hydrolyzed form of fucoxanthin is then absorbed by Caco-2
cells, then circulated by the lymphatic system23. The atypical functional oxygen groups
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are in part what gives fucoxanthin its molecular shape and unique biological function18,25.
Among fucoxanthins numerous physiological functions, their effects on obesity, diabetes,
inflammation, and dyslipidemia are extremely promising. It’s known in the field of
medicine and human health that obesity is associated with dyslipidemia, and will
negatively impact inflammatory cytokines, which may cause type 2 diabetes26,27.
Obesity
The prevalence of obesity is far-reaching, showing prevalence in all races, sexes,
and ages within the United States, and has become the most prevalent metabolic disease
in the modern world28–32. Screening for obesity in a clinical setting can be done by
calculating an individual’s body mass index (BMI) by using a person’s height and
weight, with the highest risk group for developing chronic disease being those with a
BMI greater than 29.9kg/m²33. While BMI may have limitations on describing body
fatness for all individuals, it provides an effective estimation of body fatness for most
patients within a clinical setting33,34. With rates of obesity in the United States being
projected to continually increase30,35, alternative routes to help individuals manage their
obesity, such as pharmacological aids and bariatric surgery amongst other plans, are
constantly being developed and implemented36–38. Adipose tissue is comprised of two
different subtypes of adipose, referred to as white adipose tissue (WAT) and brown
adipose tissue (BAT). The main difference between WAT and BAT, with concerns to this
review, is that BAT contains uncoupling protein-1 (UCP1)39. While UCP1 mRNA is
found both within BAT, as well as WAT, but largely lay unexpressed, and dormant in
most WAT cells, unless exposed to certain environmental factors such as extreme cold.
UCP1 expression upregulating within WAT cells is reffered to as “browning”, as the
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tissue now displays the metabolic characteristics of BAT40 . UCP1 is found within the
inner membrane of the mitochondria of BAT, and when UCP1 is upregulated, protons
outside of the mitochondrial space are taken by the UCP1 to produce heat
(thermogenesis) rather than being utilized for energy41–45.
Murine rat models and limited human trials have revealed promising capabilities
that fucoxanthin supplementation has the unique capability to induce UCP1 expression in
WAT to stimulate whole-body adipose tissue loss10,11,18,46. A murine model study that
was performed by Maeda et. al (2005) revealed that when KK-A(y) mice and Wister rats
were fed either 0.32% or 1.3% fucoxanthin by weight of diet for four weeks, UCP1
expression was almost 5 times higher in WAT when compared to the control group.
WAT tissue relative to total body weight was over 25% lower in the fucoxanthin-fed
group, indicating the increased UCP1 expression within the WAT lead to overall weight
loss 46. The fucoxanthin-fed mice and rats also had significantly lower body weight when
compared to the control group, which can be solely attributed to the loss of WAT as there
was no significant difference in the mean daily feeding intake, or other lifestyle factors
between the fucoxanthin group and the control group46.
In a study by Gille et. al, researchers revealed that after 26 days, C57BL/6 mice
gained less body fat when being fed a fucoxanthin-rich phaedoactylum triconutum extract
(PTE) when compared to the placebo group. Gille et. al also found that the two groups of
mice being fed either 2.4 mg/kg body weight or 7.1 mg/kg bodyweight of fucoxanthin
had as high as 11x higher UCP1 expression compared to the placebo mice47. In the only
human study of fucoxanthin’s effects on body fat, Abidov et. al found that when obese
women supplemented with 2.4 mg of fucoxanthin for 16 weeks, they lost an average of
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7.94 lb of body fat and had an average of a 5cm decrease in waist circumference when
compared to the placebo group48. While there is no current literature observing the
expression of UCP1 in WAT of a human subject supplementing with fucoxanthin, the
loss in body fat presented by Abidov et. al shows promise for the potential of UCP1
expression in WAT similar to those of Madea’s research in rats.
Diabetes
Globally, type 2 diabetes mellitus (T2DM) has rapidly become one of the largest
public health concerns49. T2DM is an extremely complex polygenic condition in which
individuals have blunted insulin secretion or action (insensitivity), causing hyperglycemia
and impaired carbohydrate metabolism50–52. Various medications, diets, exercise
interventions, and even bariatric surgery have all been shown to be effective routes in
treating T2DM53–58, with the most popular non-insulin-based drug being metformin59–64.
Research conducted in murine models revealed that fucoxanthin may decrease
blood glucose through a myriad of actions stemming from fucoxanthin’s ability to
upregulate glucose transporter 4 (GLUT4) in muscle tissue8. Maeda et. al showed that
after 4 weeks, out of the 24 obese C57BL/6 mice, the groups that were fed a high-fat diet
enriched with either 1.06%, or 2.22% fucoxanthin, sourced from wakame lipids, had the
same muscular GLUT4 activity, as well as plasma insulin and blood glucose levels as the
non-obese mice8. Another murine model using C57BL/6 mice from Gille et. al, showed
that after 26 days, the obese mice who received 2.4 mg/kg body weight, or 7.1 mg/kg
bodyweight of fucuxanthin had lower plasma insulin levels (27.7 mU/L and 33.5 mU/L,
respectively) when compared to the placebo group (42.1 mU/L)47. Interestingly, the
group that received the 2.4 mg/kg treatment had significantly lower 6 hour fasted plasma
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glucose (134 mg/dL) when compared to the group that was supplemented with 7.1 mg/kg
(179 mg/dL), who had plasma glucose levels higher than the placebo group (161
mg/dL)47. Through it’s utility in decreasing blood glucose using different pathways from
pharmaceutical intervention, metformin, fucoxanthin may prove in the future to be a
potential treatment option for those who cannot tolerate the GI discomfort from
metformin, and may also serve as an additive prescriptive to an already metformin based
intervention.
Inflammation
Both chronic and acute inflammation is induced by the production of
inflammatory cytokines in response to a stressor, and when left unchecked, chronically
high-stress levels can lead to increased risk of non-communicable chronic disease
development65,66. Interleukin-6 (IL-6) is a cytokine heavily involved in acute and chronic
inflammatory responses, as well as the regulation of various metabolic processes67–70. IL6 has been demonstrated to play a critical role in the development and progression of
pancreatic cancer tumor growth by stimulating cancerous neoplastic cells71. By blocking
IL-6 activity via prescription Tocilizumab, researchers have been able to effectively treat
the autoimmune disease rheumatoid arthirits72. Neutralizing IL-6 via IL-6 antibodies has
beneficial effects in other autoimmune diseases such as Castleman’s Disease, and
juvenile idiopathic arthritis68.
Tumor necrosis factor apha (TNF-α) is another inflammatory cytokine that is
responsible for inducing cellular apoptosis, and activation of the proinflammatory nuclear
factor-kB pathway(NF-kB)73. TNF-α directly impairs the signaling and responsiveness of

9

insulin by upregulating serine phosphorylation on insulin receptor substrate 1 (IRS-1),
leading to the development of insulin resistance74,75.
Fucoxanthin has the ability to attenuate tumor necrosis factor-alpha (TNF-α), and
leptin levels, both of which contribute to insulin resistance76,77. The same study
previously mentioned in this section from Maeda et. al revealed that the C57BL/6 mice
had more than 60% lower TNF-α levels after being fed a high-fat diet enriched with
fucoxanthin when compared to the control group, and the high-fat diet group who did not
get the fucoxanthin8. Maeda et. al also showed that leptin mRNA levels expression was
significantly lower in the groups being fed a high-fat diet, enriched with fucoxanthin
when compared to the high-fat diet group that did not receive the fucoxanthin8.
Fucoxanthin supplementation has exhibited decreases in IL-6 and TNF-α in
another murine model study from Jiang et. al using ICR mice. Seven days before
treatment with a lipopolysaccharide injection, the group of ICR mice that were treated
with 200 mg/kg of fucoxanthin had up to 55% lower concentration of IL-6 and TNF-α in
the hippocampus when compared to the group that received no fucoxanthin treatment.
The same mice treated with 200 mg/kg of fucoxanthin showed up to a 59% lower
concentration of IL-6 and TNF-α in the frontal cortex, and up to a 51.9% lower
concentration of IL-6 and TNF-α in the hypothalamus when compared to the group of
mice that did not receive the fucoxanthin treatment78. The group of mice treated with 200
mg/kg of fucoxanthin also showed lower significantly lower expressions of NF-kB in the
hippocampus, hypothalamus, and frontal cortex, indicating that one of the fucoxanthins
potential routes of inflammation attenuation is by inhibiting the NF-kB pathway78. The
mechanisms in how fucoxanthin inhibits the NF-kB pathway are currently still unclear79,
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but these preliminary studies provide the groundwork for future research to explore
fucoxanthin’s mechanism(s) of action in inflammation.
Hyperlipidemia
Hyperlipidemia is a condition characterized by the elevation of serum
triglycerides and/or low-density lipoprotein cholesterol (LDL-C) and is a strong risk
factor for the development of cardiovascular disease (CVD)80–82. Hyperlipidemia impacts
the function of vascular endothelial cells by damaging the vascular wall83.
Pharmaceutical treatments such as statins work to reduce LDL-C84,85, by inhibiting
endogenous cholesterol production. While statins are successful at attenuating
hyperlipidemia, they are also associated with negative side effects such as myopathy86,
development of T2DM87, and potential hemorrhagic strokes in those who have high
blood pressure88,89. The supplementation of fucoxanthin may be a unique treatment for
those with hyperlipidemia that either prefer to not use statins, or who perhaps cannot
tolerate statins as part of their treatment plan.
In murine model experiments, fucoxanthin demonstrates promise as a potential
treatment for hyperlipidemia, by having multiple effects on lipid profiles. Beppu et. al
found that in obese KK-A(y) mice, that after 4 weeks of being on a diet containing 0.2%
fucoxanthin increased serum serum high-density lipoprotein cholesterol (HDL-C) by 50
mg/dL, and reduced the amount of total cholesterol found in the liver by 4.6 mg90. Maeda
et. al explored the effect of fucoxanthin in mice during a high-fat diet and found that after
feeding C57BL/6 mice a high-fat diet, the groups receiving 1.06% and 2.22%
fucoxanthin had up to 53% lower LDL-C when compared to the high-fat non-fucoxanthin
group8. Research from Ha et. al has revealed that rats who were on a high-fat diet made
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up of 0.2% fucoxanthin for 4 weeks had 158% higher plasma HDL-C and 23% lower
serum triglycerides, as well as 46% lower total liver cholesterol and 41% lower liver
triglycerides, compared to the high-fat diet without fucoxanthin or a control diet groups91.
These lipid-altering actions can be attributed to fucoxanthin downregulating the
mRNA expression of SREBP-1c, a gene in which controls the lipogenic enzymes AcetylCoA carboxylase, fatty acid synthase, and glucose-6-phosphate dehydrogenase91.
Fucoxanthin has also demonstrated the capability to upregulate CYP7A1 gene expression
in the liver, causing more fecal excretion of cholesterol91. The aforementioned data
collected insinuates that fucoxanthin supplementation, in addition to, or in replacement of
a statin-based treatment regimen, may help decrease serum total cholesterol, LDL-C, and
triglycerides, as well as increasing serum HDL-C.
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Discussion
In conclusion, fucoxanthin has the potential mechanisms to postivitley impact
many different aspects of human health. Not only obesity, but glucose management,
inflammation, and dyslipidemia may all be aided by fucoxanthin’s promising effects.
Fucoxanthin has implications as a potential clinical intervention to help those who are
overweight/obese, as these individuals can typically benefit from increased GLUT4
translocation, decreased adiposity, reduced inflammation, and lipid profile improvements.
If fucoxanthin were to be used to attenuate any of the previously mentioned areas of
health, there would be potential beneficial outcomes in other areas of health such as using
fucoxanthin to reduce blood glucose, but also achieving a reduction in LDL-C for a
patient with T2DM.
The current landscape of literature is limited by numerous factors. As it stands,
the majority of fucoxanthin-based research has been done in mouse model research. More
research needs to be done in various human populations to examine fucoxanthin’s true
effects on human health, as opposed to discussing its potential health effects for humans.
In human studies, an established dose of fucoxanthin for supplementation should be
investigated based on the desired health outcome. Hand in hand with an established
dosage, researchers should elucidate any negative side effects, as well any interactions
with other pharmaceutical or nutraceutical interventions, currently no human studies
suggest harmful side effects. Long-term supplementation studies are another area of
continued research that needs to be further established so that clinicians be aware of how
long an individual can supplement with fucoxanthin. Further research is needed to
elucidate more of fucoxanthin’s mechanisms of action that haven’t yet been discovered,
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such as exactly how fucoxanthin affects the expression of the NF-kB pathway, as well as
UCP1 genes, and the expression of mRNA signaling of Acetyl-CoA carboxylase, fatty
acid synthase, and glucose-6-phosphate dehydrogenase via SREBP-1c. An investigation
as to whether fucoxanthin will have a larger lipolytic effect on subcutaneous adipose
tissue, or visceral adipose tissue may also prove to provide further insight into
fucoxanthins use case. Fucoxanthin offers unique potential to be a nutraceutical treatment
option for those who are obese, as fucoxanthin not only directly attenuates obesity, but
also will attenuate the commonly associated co-morbidites of obesity, being T2DM,
chronic inflammation, and hyperlipidemia.
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Figure 1. CONSORT Diagram
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Table 1. In Vivo Fucoxanthin Research Effecting Obesity
Title

Author Subjects

Treatment

Results

Anti-obesity and anti-diabetic effects of
fucoxanthin on diet-induced obesity conditions
in a murine model

Madea
et. al

C57BL/J Mice

1.06% or 2.22% fucoxanthin by weight
of diet

Higher weight loss in FX groups,
WAT gain was suppressed in FX
group. Leptin mRNA expression
up to 89% lower in the FX group.

Dietary Combination of Fucoxanthin and Fish
Oil Attenuates the Weight Gain of White
dipose Tissue and Decreases Blood Glucose in
Obese/Diabetic KK-Ay Mice

Madea
et. al

KK-Ay Mice

0.2% Fucoxanthin, or 0.1% Fucoxanthin
+ 6.9% Fishoil by weight of diet

FX treated mice were 6.4g lighter
on average compared to control
group.

Fucoxanthin from edible seaweed, Undaria
pinnatifida, shows antiobesity effect through
UCP1 expression in white adipose tissues

Madea
et. al

Male Wistar
Rates, Female
KK-Ay Mice

1.3% or 0.3% Fucoxanthin by weight of
diet for four weeks

Over 25% lower WAT in Fx fed
group. UCP1 expression ~5x
higher in WAT of subjects treated
with Fx.

A Lipophilic Fucoxanthin-Rich Phaeodactylum
tricornutum Extract Ameliorates Effects of
Diet-Induced Obesity in C57BL/6J Mice

Gille et.
al

C57BL/J Mice

2.4mg fucoxanthin/kg bw or 7.1mg
fucoxanthin kg/bw for 26 days

Fx fed groups had UCP1 as high
as 11x higher expression in
inguinal WAT.

The effects of Xanthigen™ in the weight
management of obese premenopausal women
with non-alcoholic fatty liver disease and
normal liver fat

Abidov
et. al

Obese
premenopausal
women

2.4mg fucoxanthin + 300mg
pomegranate seed oil daily for 16 weeks

6.9kg +/1.9kg loss in body weight
in the Fx group. Average of 5cm
lost in waist circumference.
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Table 2. In Vivo Fucoxanthin Research Effecting Diabetes, Hyperlipidemia, and Inflammation
Title

Author Subjects

Treatment

Anti-obesity and antidiabetic effects of
fucoxanthin on dietinduced obesity
conditions in a murine
model

Madea
et. al

C57BL/J Mice

1.06% or 2.22%
fucoxanthin by weight of
diet for 26 days

Dietary Combination of
Fucoxanthin and Fish
Oil Attenuates the
Weight Gain of White
dipose Tissue and
Decreases Blood
Glucose in
Obese/Diabetic KK-Ay
Mice

Madea
et. al

KK-Ay Mice

0.2% Fucoxanthin, or
0.1% Fucoxanthin + 6.9%
Fish oil by weight of diet

Beppu
et. al

KK-Ay Mice

0.2% Fucoxanthin by
weight of diet for 4 weeks

Gille et.
al

C57BL/J Mice

2.4mg fucoxanthin/kg bw
or 7.1mg fucoxanthin
kg/bw for 26 days

Ha et. al

SpragueDawley rats

4% Fucoxanthin by weight
of diet for 4 weeks

Effects of dietary
fucoxanthin on
cholesterol metabolism
in diabetic/obese KK-Ay
mice
A Lipophilic
FucoxanthinRich Phaeodactylum
tricornutum Extract
Ameliorates Effects of
Diet-Induced Obesity in
C57BL/6J Mice
The effect of
fucoxanthin rich power
on the lipid metabolism

Effects on
Diabetes

Effects on
Hyperlipidemia

Fx group
regained healthy
GLUT4 levels in
muscle tissue by
the end of a high
fat diet.

Blood improved
glucose and
insulin in FX fed
groups.

53% lower LDL-C
in Fx group
compared to
control group.

Serum HDL 50
mg/dL higher, and
4.6g less liver
cholesterol in Fx
fed rats.

Fx treated mice
had 45 mg/dL
lower plasma
insulin.

.

158% higher
plasma HDL-C,
46% lower liver

Effects on
Inflammation
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in rats with a high fat
diet.

cholesterol, and
41% lower liver
triglycerides in the
Fx fed group when
compared to
control.
Fx group also had
lower expression of
SREBP-1c mRNA.
CYP7A1 gene
expressed higher in
Fx fed groups
compared to
control.

Fucoxanthin prevents
lipopolysaccharideinduced depressive-like
behavior in mice via
AMPK- NF-κB
pathway.

Jiang et.
al

ICR Mice

Control +200mg/kg FX
Lipopolysaccharide +
50mg/kg FX,
Lipopolysaccharide +
100mg/kg FX
Lipopolysaccharide +
200mg/kg FX

LPS+200 mg/kg of
Fx group had 55%,
59%, and 51.9%
lower IL-6 and
TNF-α in the
hippocampus,
frontal cortex, and
hypothalamus,
respectively.
LPS+200 mg/kg
Fx group also had
lower NF-kB
expression
compared to
control.

18

References
1.

Natsume C, Aoki N, Aoyama T, et al. Fucoxanthin Ameliorates Atopic Dermatitis
Symptoms by Regulating Keratinocytes and Regulatory Innate Lymphoid Cells. Int
J Mol Sci. 2020;21(6). doi:10.3390/ijms21062180

2.

Kang SY, Kang H, Lee JE, et al. Antiaging Potential of Fucoxanthin Concentrate
Derived from Phaeodactylum tricornutum. J Cosmet Sci. 2020;71(2):53-64.

3.

Foo SC, Yusoff FM, Imam MU, et al. Increased fucoxanthin in Chaetoceros
calcitrans extract exacerbates apoptosis in liver cancer cells via multiple targeted
cellular pathways. Biotechnol Rep Amst Neth. 2019;21:e00296.
doi:10.1016/j.btre.2018.e00296

4.

Garg S, Afzal S, Elwakeel A, et al. Marine Carotenoid Fucoxanthin Possesses AntiMetastasis Activity: Molecular Evidence. Mar Drugs. 2019;17(6).
doi:10.3390/md17060338

5.

Satomi Y. Antitumor and Cancer-preventative Function of Fucoxanthin: A Marine
Carotenoid. Anticancer Res. 2017;37(4):1557-1562. doi:10.21873/anticanres.11484

6.

Terasaki M, Ikuta M, Kojima H, et al. Dietary Fucoxanthin Induces Anoikis in
Colorectal Adenocarcinoma by Suppressing Integrin Signaling in a Murine
Colorectal Cancer Model. J Clin Med. 2019;9(1). doi:10.3390/jcm9010090

7.

Wang J, Ma Y, Yang J, et al. Fucoxanthin inhibits tumour-related
lymphangiogenesis and growth of breast cancer. J Cell Mol Med. 2019;23(3):22192229. doi:10.1111/jcmm.14151

8.

Maeda H, Hosokawa M, Sashima T, Murakami-Funayama K, Miyashita K. Antiobesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions
in a murine model. Mol Med Rep. 2009;2(6):897-902. doi:10.3892/mmr_00000189

9.

Gammone MA, D’Orazio N. Anti-Obesity Activity of the Marine Carotenoid
Fucoxanthin. Mar Drugs. 2015;13(4):2196-2214. doi:10.3390/md13042196

10. Miyashita K, Nishikawa S, Beppu F, Tsukui T, Abe M, Hosokawa M. The allenic
carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. J Sci
Food Agric. 2011;91(7):1166-1174. doi:10.1002/jsfa.4353
11. Mikami K, Hosokawa M. Biosynthetic pathway and health benefits of fucoxanthin,
an algae-specific xanthophyll in brown seaweeds. Int J Mol Sci. 2013;14(7):1376313781. doi:10.3390/ijms140713763
12. Wejdling K. XXXII.:The Predominance of Diatoms in the Origin of Cod Liver Oil.
Acta Pædiatrica. 1928;7:259-274. doi:10.1111/j.1651-2227.1928.tb03988.x

19

13. Okuzumi J, Nishino H, Murakoshi M, et al. Inhibitory effects of fucoxanthin, a
natural carotenoid, on N-myc expression and cell cycle progression in human
malignant tumor cells. Cancer Lett. 1990;55(1):75-81. doi:10.1016/03043835(90)90068-9
14. Kotake-Nara E, Asai A, Nagao A. Neoxanthin and fucoxanthin induce apoptosis in
PC-3 human prostate cancer cells. Cancer Lett. 2005;220(1):75-84.
doi:10.1016/j.canlet.2004.07.048
15. Kotake-Nara E, Kushiro M, Zhang H, Sugawara T, Miyashita K, Nagao A.
Carotenoids Affect Proliferation of Human Prostate Cancer Cells. J Nutr.
2001;131(12):3303-3306. doi:10.1093/jn/131.12.3303
16. Murakami C, Takemura M, Sugiyama Y, et al. Vitamin A-related compounds, alltrans retinal and retinoic acids, selectively inhibit activities of mammalian
replicative DNA polymerases. Biochim Biophys Acta BBA - Gene Struct Expr.
2002;1574(1):85-92. doi:10.1016/S0167-4781(01)00348-7
17. Mann JE, Myers J. On Pigments, Growth, and Photosynthesis of Phaeodactylum
Tricornutum12. J Phycol. 1968;4(4):349-355. doi:https://doi.org/10.1111/j.15298817.1968.tb04707.x
18. Peng J, Yuan J-P, Wu C-F, Wang J-H. Fucoxanthin, a marine carotenoid present in
brown seaweeds and diatoms: metabolism and bioactivities relevant to human
health. Mar Drugs. 2011;9(10):1806-1828. doi:10.3390/md9101806
19. Shaw B, Harrison P, Andersen R. Feeding deterrence properties of apofucoxanthinoids from marine diatoms. II. Physiology of production of apofucoxanthinoids by the marine diatoms Phaeodactylum tricornutum and
Thalassiosira pseudonana, and their feeding deterrent effects on the copepod
Tigriopus californicus. Mar Biol. 1995;124:473-481. doi:10.1007/BF00363922
20. Doi Y, Ishibashi M, Yamaguchi N, Kobayashi J. Isolation of Apo-9’fucoxanthinone from the Cultured Marine Dinoflagellate Amphidinium sp. J Nat
Prod. 1995;58(7):1097-1099. doi:10.1021/np50121a020
21. Mori K, Ooi T, Hiraoka M, et al. Fucoxanthin and Its Metabolites in Edible Brown
Algae Cultivated in Deep Seawater. Mar Drugs. 2004;2(2):63-72.
doi:10.3390/md202063
22. Komba S, Kotake-Nara E, Tsuzuki W. Degradation of Fucoxanthin to Elucidate the
Relationship between the Fucoxanthin Molecular Structure and Its Antiproliferative
Effect on Caco-2 Cells. Mar Drugs. 2018;16(8). doi:10.3390/md16080275
23. Sugawara T, Baskaran V, Tsuzuki W, Nagao A. Brown Algae Fucoxanthin Is
Hydrolyzed to Fucoxanthinol during Absorption by Caco-2 Human Intestinal Cells
and Mice. J Nutr. 2002;132(5):946-951. doi:10.1093/jn/132.5.946

20

24. Méresse S, Fodil M, Fleury F, Chénais B. Fucoxanthin, a Marine-Derived
Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive
Compound for Cancer Therapy. Int J Mol Sci. 2020;21(23):9273.
doi:10.3390/ijms21239273
25. Yan X, Chuda Y, Suzuki M, Nagata T. Fucoxanthin as the Major Antioxidant in
Hijikia fusiformis , a Common Edible Seaweed. Biosci Biotechnol Biochem.
1999;63(3):605-607. doi:10.1271/bbb.63.605
26. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation:
the linking mechanism and the complications. Arch Med Sci AMS. 2017;13(4):851863. doi:10.5114/aoms.2016.58928
27. Maiuolo J, Gliozzi M, Musolino V, et al. From Metabolic Syndrome to
Neurological Diseases: Role of Autophagy. Front Cell Dev Biol. 2021;9.
doi:10.3389/fcell.2021.651021
28. Anderson SE, Whitaker RC. Prevalence of obesity among US preschool children in
different racial and ethnic groups. Arch Pediatr Adolesc Med. 2009;163(4):344-348.
doi:10.1001/archpediatrics.2009.18
29. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United
States. Obes Rev Off J Int Assoc Study Obes. 2005;6(1):5-7. doi:10.1111/j.1467789X.2005.00165.x
30. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans
become overweight or obese? estimating the progression and cost of the US obesity
epidemic. Obes Silver Spring Md. 2008;16(10):2323-2330.
doi:10.1038/oby.2008.351
31. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of Obesity Among
Adults and Youth: United States, 2011-2014. NCHS Data Brief. 2015;(219):1-8.
32. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased
adipose tissue expression of tumor necrosis factor-alpha in human obesity and
insulin resistance. J Clin Invest. 1995;95(5):2409-2415. doi:10.1172/JCI117936
33. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635-643.
doi:10.1038/35007508
34. Müller MJ. From BMI to functional body composition. Eur J Clin Nutr.
2013;67(11):1119-1121. doi:10.1038/ejcn.2013.174
35. Finkelstein M Eric A, PhD, MA OAK, BA HT, et al. Obesity and Severe Obesity
Forecasts Through 2030. Am J Prev Med. 2012;42(6):563-570.
doi:10.1016/j.amepre.2011.10.026

21

36. Burke LE, Wang J. Treatment strategies for overweight and obesity. J Nurs
Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2011;43(4):368-375.
doi:10.1111/j.1547-5069.2011.01424.x
37. Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle,
pharmacologic, and surgical options. Clin Cornerstone. 2009;9(4):55-71.
doi:10.1016/s1098-3597(09)80005-7
38. Kahan S. Overweight and obesity management strategies. Am J Manag Care.
2016;22(7 Suppl):186.
39. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell.
2014;156(1-2):20-44. doi:10.1016/j.cell.2013.12.012
40. Abdullahi A, Jeschke MG. White Adipose Tissue Browning: a double edge sword.
Trends Endocrinol Metab TEM. 2016;27(8):542-552.
doi:10.1016/j.tem.2016.06.006
41. Chouchani ET, Kazak L, Spiegelman BM. New Advances in Adaptive
Thermogenesis: UCP1 and Beyond. Cell Metab. 2019;29(1):27-37.
doi:10.1016/j.cmet.2018.11.002
42. Porter C. Quantification of UCP1 function in human brown adipose tissue.
Adipocyte. 2017;6(2):167-174. doi:10.1080/21623945.2017.1319535
43. Boon MR, van Marken Lichtenbelt WD. Brown Adipose Tissue: A Human
Perspective. Handb Exp Pharmacol. 2016;233:301-319. doi:10.1007/164_2015_11
44. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological
significance. Physiol Rev. 2004;84(1):277-359. doi:10.1152/physrev.00015.2003
45. Klingenberg M. Uncoupling proteins–how do they work and how are they regulated.
IUBMB Life. 2001;52(3-5):175-179. doi:10.1080/15216540152845975
46. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from
edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1
expression in white adipose tissues. Biochem Biophys Res Commun.
2005;332(2):392-397. doi:10.1016/j.bbrc.2005.05.002
47. Gille A, Stojnic B, Derwenskus F, et al. A Lipophilic Fucoxanthin-Rich
Phaeodactylum tricornutum Extract Ameliorates Effects of Diet-Induced Obesity in
C57BL/6J Mice. Accessed February 21, 2021. https://www.mdpi.com/20726643/11/4/796/htm
48. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of Xanthigen in the
weight management of obese premenopausal women with non-alcoholic fatty liver
disease and normal liver fat. Diabetes Obes Metab. 2010;12(1):72-81.
doi:10.1111/j.1463-1326.2009.01132.x

22

49. Pandey A, Chawla S, Guchhait P. Type-2 diabetes: Current understanding and
future perspectives. IUBMB Life. 2015;67(7):506-513. doi:10.1002/iub.1396
50. Pearson ER. Type 2 diabetes: a multifaceted disease. Diabetologia.
2019;62(7):1107-1112. doi:10.1007/s00125-019-4909-y
51. Udler MS. Type 2 Diabetes: Multiple Genes, Multiple Diseases. Curr Diab Rep.
2019;19(8):55. doi:10.1007/s11892-019-1169-7
52. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk Factors Contributing to Type 2 Diabetes
and Recent Advances in the Treatment and Prevention. Int J Med Sci.
2014;11(11):1185-1200. doi:10.7150/ijms.10001
53. Courcoulas AP, Belle SH, Neiberg RH, et al. Three-Year Outcomes of Bariatric
Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A
Randomized Clinical Trial. JAMA Surg. 2015;150(10):931.
doi:10.1001/jamasurg.2015.1534
54. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric Surgery versus Conventional
Medical Therapy for Type 2 Diabetes. N Engl J Med. 2012;366(17):1577-1585.
doi:10.1056/NEJMoa1200111
55. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical
Therapy for Diabetes — 3-Year Outcomes. N Engl J Med. 2014;370(21):20022013. doi:10.1056/NEJMoa1401329
56. Salas-Salvado J, Bullo M, Babio N, et al. Reduction in the Incidence of Type 2
Diabetes With the Mediterranean Diet: Results of the PREDIMED-Reus nutrition
intervention randomized trial. Diabetes Care. 2011;34(1):14-19. doi:10.2337/dc101288
57. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of
Glycemic Responses. Cell. 2015;163(5):1079-1094. doi:10.1016/j.cell.2015.11.001
58. Li Z, Hu Y, Yan R, et al. Twenty Minute Moderate-Intensity Post-Dinner Exercise
Reduces the Postprandial Glucose Response in Chinese Patients with Type 2
Diabetes. Med Sci Monit. 2018;24:7170-7177. doi:10.12659/MSM.910827
59. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.
doi:10.1007/s00125-017-4318-z
60. Diabetes Prevention Program Research Group. Long-term Effects of Metformin on
Diabetes Prevention: Identification of Subgroups That Benefited Most in the
Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Diabetes Care. 2019;42(4):601-608. doi:10.2337/dc18-1970
61. Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J.
Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics.

23

Curr Pharm Des. 2017;23(17):2532-2550.
doi:10.2174/1381612822666161201152941
62. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes.
Diabetologia. 2017;60(9):1586-1593. doi:10.1007/s00125-017-4336-x
63. RISE Consortium. Impact of Insulin and Metformin Versus Metformin Alone on βCell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed
Type 2 Diabetes. Diabetes Care. 2018;41(8):1717-1725. doi:10.2337/dc18-0787
64. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes.
Diabetologia. 2017;60(9):1586-1593. doi:10.1007/s00125-017-4336-x
65. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of
disease across the life span. Nat Med. 2019;25(12):1822-1832. doi:10.1038/s41591019-0675-0
66. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential
Contribution to Age-Associated Diseases. J Gerontol A Biol Sci Med Sci.
2014;69(Suppl 1):S4-S9. doi:10.1093/gerona/glu057
67. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F.
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem
J. 2003;374(1):1-20. doi:10.1042/bj20030407
68. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the
pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-1247.
doi:10.7150/ijbs.4989
69. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease.
Cold Spring Harb Perspect Biol. 2014;6(10):a016295.
doi:10.1101/cshperspect.a016295
70. The pro- and anti-inflammatory properties of the cytokine interleukin-6 | Elsevier
Enhanced Reader. doi:10.1016/j.bbamcr.2011.01.034
71. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 Activation by IL-6
Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and
Development of Pancreatic Cancer. Cancer Cell. 2011;19(4):456-469.
doi:10.1016/j.ccr.2011.03.009
72. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell
Arteritis. N Engl J Med. 2017;377(4):317-328. doi:10.1056/NEJMoa1613849
73. Leong KG, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha.
Histol Histopathol. 2000;15(4):1303-1325. doi:10.14670/HH-15.1303

24

74. Gual P, Le Marchand-Brustel Y, Tanti J-F. Positive and negative regulation of
insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87(1):99-109.
doi:10.1016/j.biochi.2004.10.019
75. Borst SE. The role of TNF-αlpha in insulin resistance. Endocrine. 2004;23(23):177-182. doi:10.1385/ENDO:23:2-3:177
76. Maeda H, Hosokawa M, Sashima T, Miyashita K. Dietary combination of
fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and
decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem.
2007;55(19):7701-7706. doi:10.1021/jf071569n
77. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin
resistance. Clin Chim Acta. 2013;417:80-84. doi:10.1016/j.cca.2012.12.007
78. Jiang X, Wang G, Lin Q, Tang Z, Yan Q, Yu X. Fucoxanthin prevents
lipopolysaccharide-induced depressive-like behavior in mice via AMPK- NF-κB
pathway. Metab Brain Dis. 2019;34(2):431-442. doi:10.1007/s11011-018-0368-2
79. Kim K-N, Heo S-J, Yoon W-J, et al. Fucoxanthin inhibits the inflammatory
response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharideinduced RAW 264.7 macrophages. Eur J Pharmacol. 2010;649(1-3):369-375.
doi:10.1016/j.ejphar.2010.09.032
80. Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim Care
Clin Off Pract. 2013;40(1):195-211. doi:10.1016/j.pop.2012.11.003
81. Navar-Boggan AM, Peterson ED, D’Agostino RB, Neely B, Sniderman AD,
Pencina MJ. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of
Coronary Heart Disease. Circulation. 2015;131(5):451-458.
doi:10.1161/CIRCULATIONAHA.114.012477
82. Karr S. Epidemiology and Management of Hyperlipidemia. :10.
83. McCrindle BW. Hyperlipidemia in children. Thromb Res. 2006;118(1):49-58.
doi:10.1016/j.thromres.2005.01.006
84. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of Two Intensive Statin
Regimens on Progression of Coronary Disease. N Engl J Med. 2011;365(22):20782087. doi:10.1056/NEJMoa1110874
85. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy
on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA.
2006;295(13):1556. doi:10.1001/jama.295.13.jpc60002
86. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle
problems in clinical trials. Am Heart J. 2014;168(1):6-15.
doi:10.1016/j.ahj.2014.03.019

25

87. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a
collaborative meta-analysis of randomised statin trials. The Lancet.
2010;375(9716):735-742. doi:10.1016/S0140-6736(09)61965-6
88. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL
cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. The Lancet.
2012;380(9841):581-590. doi:10.1016/S0140-6736(12)60367-5
89. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55 000 vascular deaths.
The Lancet. 2007;370(9602):1829-1839. doi:10.1016/S0140-6736(07)61778-4
90. Beppu F, Hosokawa M, Niwano Y, Miyashita K. Effects of dietary fucoxanthin on
cholesterol metabolism in diabetic/obese KK-Ay mice. Lipids Health Dis.
2012;11(1):112. doi:10.1186/1476-511X-11-112
91. Ha AW, Kim WK. The effect of fucoxanthin rich power on the lipid metabolism in
rats with a high fat diet. Nutr Res Pract. 2013;7(4):287.
doi:10.4162/nrp.2013.7.4.287

